In this issue:
- Adjuvant nivolumab in completely resected Merkel cell carcinoma
- Real-world vismodegib for advanced and multiple BCCs
- Impact of clinical and histopathological characteristics on DFS in stage I–II acral melanoma
- External validation of MIAs sentinel node metastasis risk prediction tool
- Bempegaldesleukin + nivolumab in untreated advanced melanoma
- Histological margin status predicts maligna melanoma relapse
- Neoadjuvant cemiplimab and surgery for stage II–IV cutaneous SCC
- OCT for diagnosing recurrent or residual BCCs after topical treatment
- Contribution of MEK inhibition in BRAF/MEK inhibitor combination for BRAF-mutant melanoma
- Differentiating lentigo maligna from other atypical pigmented facial lesions
Please login below to download this issue (PDF)